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Abstract CAP18 is an antimicrobial protein found in specific 
granules of PMNs. The human CAP18 (HCAP18) gene was 
cloned from a human genomic phage library. Sequence analysis 
revealed the HCAPI8 gene to have 4 exons spanning 3 kb, 
including 700 bp of upstream DNA. Using 3' RACE no homologs 
of human HCAP18 were found in human bone marrow or 
leukocyte populations. By PCR analysis of a somatic cell 
mapping panel and fluorescence in situ hybridization of a 
genomic lone to metaphase chromosomes the gene was mapped 
to chromosome band 3p21.3. Like several other genes expressed 
late in PMN development he CAP18 gene did not contain 
typical TATA box or CCAAT sequences. Expression in Cos 7 
cells permitted limited mapping of the promoter function in 
upstream fragments of the HCAP18 gene. Western blot, 
Northern blot and RT-PCR analysis show HCAP18 to be 
produced specifically in granulocytes. This work forms the 
groundwork for future analysis of the genetic regulation of this 
antimicrobial protein during PMN differentiation. 
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1. Introduction 
Since the discovery of penicillin by Fleming in the 1920s 
several hundred antibiotics have been identified and used 
clinically. Misuse of these miracle drugs has selected a 
plethora of drug resistant microbial strains and the search 
for novel antibiotics continues. The identification of verte- 
brate peptides with broad spectrum antimicrobial activity 
has opened a new era of 'endobiotic therapy' for infectious 
diseases [1]. Among the most promising are those antimicro- 
bial peptides identified in mammalian PMNs. These proteins 
include the defensins [2,3], BPI [4,5], CAP37 [6] and members 
of the CAP18 family [7]. 
CAP18 (18-kDa cationic antimicrobial protein) was first 
identified, purified and cloned from rabbit leukocytes [8]. 
CAP18 and derivative peptides possess a number of functions 
important for host defense. These include: binding to and, 
attenuation of many of the biological activities of lipopolysac- 
charides of diverse origin; cytotoxicity for Gram-positive and 
Gram-negative bacteria and modulation of the clotting cas- 
cade. 
The family of CAP18 antimicrobial proteins hare a similar 
overall structure: signal sequence, conserved N-terminal pro- 
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sequence of unknown function and a C-terminal antimicrobial 
domain. The CAP18 mRNA is expressed predominantly in
neutrophils, where the protein accumulates in the specific 
granules. However, the mechanisms of tissue-specific expres- 
sion and protein processing are not well understood. To an- 
swer these questions, we cloned the genomic DNA for human 
CAP18, studied the structure of its promoter, and examined 
CAP18 tissue-specific expression using Western blot analysis, 
RT-PCR and Northern blot analysis. Although the human 
CAP18 cDNA was previously identified by us [9] and others 
[10,11], the chromosomal location and gene structure had not 
been determined. We report here that the HCAP18 gene is 
located on chromosome band 3p21.3 and is comprised of 
4 exons spanning 3 kb including 700 bp of upstream DNA. 
Some unusual features of the HCAP18 promoter are dis- 
cussed. 
2. Materials and methods 
2.1. Reagents 
Buffy coats were obtained from the Stanford University Blood 
Bank. Ficoll-hypaque was purchased from Sigma Chemical Co. (St. 
Louis, MO). Restriction enzymes and DNA modifying enzymes were 
purchased from Promega (Madison, WI). Bacterial culture media, cell 
culture media, lipofectamine, biochemical reagents, and antibiotics 
were supplied by Life Technologies (Gaithersburg, MD). Human 
genomic libraries, labeling kits and Northern blots were purchased 
from Clontech (Palo Alto, CA). Protein gels, kits for purification of 
mRNAs and Western blot kits were supplied by Novagen (Madison, 
w~). 
2.2. Cloning and sequencing ofHCAP18 genomic DNA 
A human genomic DNA library constructed in lambda EMBL3 
(Clontech) was screened by hybridization with a labeled probe pre- 
pared by PCR using HCAP18 specific primers designed from the hu- 
man CAP18 cDNA [9] (HUCAP no. 1: 5'-CTCAGCTACAAG- 
GAAGCTGTGCTTCGTGC-3' ; and HUCAP no. 2: 5'- 
TGTCTCCTTCACTGTGAAGCTCACAGG-3'). HCAP18 cDNA 
was amplified by PCR using the following thermal cycling param- 
eters: 95°C, 5 min; then 20 cycles of 94°C, 1 min; 55°C, 1 min; 
72°C, 1 min; followed by 72°C, 7 min. Hybridization and washing 
methods followed the Clontech manual. For restriction mapping, 
lambda clones were purified with phage purification kit (Qiagen, 
Chatsworth, CA) and digested with BamHI, EcoRI, HindlIl, PstI, 
NcoI, and SacI. The HCAP18 sequences are deposited in the Gen- 
Bank Database, accession umber U19970 (cDNA) and U48795 
(genomic). 
2.3. Characterization f 5' upstream region 
Luciferase and 13-galactosidase were used as a reporter genes. The 5' 
upstream regions constructed by PCR were subcloned into pGL3 and 
pGal (Promega) by PCR with Pfu polymerase (Stratagene, La Jolla, 
CA) using the following primers: 
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5P: : 5'-GACCGAATTCCACCCTGGCAGGCAGCCACGG-3'; 
5P2: 5'-GAGCGAATTCTGAAGAACCCACTTCCTCATC-3' ;
5P~: 5'-CTGCGAATTCGTCGCCTCGGCACCTGGCTCTC-3' ; 
5P4: 5'-CTGCGAATTCCTTAATCGATGCCTACAGGGTG-3' ; 
5P:,: 5'-CGTCGAATTCGTCTCGAACTCCTTATCTCAGG-3' ; 
5p7: 5'-CGTCGAGCTCTCATACTGAGTCTCACTCTG-3' ; 
3P 5'-CGTGGGCTCCGGTCCCCATGTCTGCCTCCCTCTAG-3'. 
\11 of the subclones were confirmed by sequencing. Each clone (2 
g~ was transfected into Cos 7 cells using Gibco-BRL Lipofectamine 
(6 ~tl) and analyzed at 24 h and transfected into K562, U937, and 
HI ,60 cell lines using the Bio-Rad Gene Pulse II (BioRad, Richmond, 
C,,). The conditions used were: 960 gF, 0.2 kV in a 0.5 ml cuvette. 
Tie medium was changed with DMEM containing 10% FBS. After 
24 48 h incubation, transfected cells were extracted and assayed for 
lu~iferase activity in a scintillation counter (Packard Instruments, 
D,,wner's Grove, IL) using kits from Promega. To measure histo- 
ch "mically, expression of the [3-galactosidase gene was detected by 
st~ ining with X-gal substrate after fixing the transfected cells. 
2.- . Somatic cell hybrid panel and PCR amplifications 
Fhe HCAPI8 gene was assigned to a human chromosome by using 
a napping panel containing 15 human×Chinese hamster somatic 
h? ~rid cell lines derived from several independent fusion experiments 
a~ 1 contain defined subsets of human chromosomes ( ummarized in
[1 ]). HCAP18-specific primers were designed from prosequences of
tb~ gene. The primers were HUCAP no. 1 and HUCAP no. 2 shown 
al:.~ve. The genomic DNA samples from the panel were amplified by 
P~ R using the conditions: 95°C, 5 min; then 35 cycles of 94°C, 
1 nin; 58°C, 1 rain; 72°C, 1 rain; followed by 72°C, 7 min. The 
P~ !R products were electrophoresed in a 2% agarose gel and visual- 
iz, d by ethidium bromide staining. 
2..  Fluorescence in situ hybridization 
Fluorescence chromosomal in situ hybridization (FISH) was per- 
fc med as an independent approach to define further the chromoso- 
mtl localization of the HCAP18 gene according to a protocol as 
dc;cribed [13]. Briefly, a genomic clone of HCAP18 with an 8 kb 
in err was labeled with biotin-16-dUTP by nick-translation using com- 
mercial reagents (Boehringer Mannheim, Indianapolis, IN). The 
la nbda clone was isolated from the Clontech human genomic library 
ald subcloned into pUCI8 after restriction mapping. Labeled probe 
w s annealed to cold competitor human placental DNA in the pres- 
e~se of salmon sperm DNA as carrier and hybridized at a concentra- 
ti, n of 100 200 ng/25 I.tl per slide to pre-treated and denatured me- 
ta ~hase (as described recently [14]) chromosomes from a human 
pt ripheral blood lymphocyte culture. Hybridization, washing, signal 
dttection and imaging by CCD camera were carried out as described. 
B ~ck-wbite photographs were generated from PICT files. 
2. ;. 5' and 3' RACE 
Human bone marrow mRNAs and peripheral blood leukocyte 
m!~,NAs (Clontech) were used for the template. The 5' RACE and 
3' RACE systems of Life Technologies were used. In 5' RACE, HC3 
(5 -TCTCCTTCACTGTGAAGCTCACAGGAAAAA-Y) for cDNA 
s) 1thesis and UAP and HUCAP no. 1 (5'-GCTTTGGCGTGTCT- 
G 3GTCCCC-Y) for PCR primers were used (conditions of PCR: 
%°C× 1 min, 55°C× 1 min, 72°CX2 min, 35 cycles). PCR products 
w .re cloned into a TA cloning vector (Invitrogen). After isolation of 
cl rues, sequencing analysis was performed using M13 reverse and 
fcrward primers. The initiation site was based on the ends of the 
se tuence obtained. 
For 3' RACE, an adaptor primer for cDNA synthesis and UAP 
a, ~ d a specific 3' RACE primer (sequence: 5'-AGCTTCACATG- 
T \AGGAGACAG-3') for PCR primers were used (conditions of 
P,;R: 94°C× 1 min, 45 55°Cx 1 min, 72°C×2 min, 35 cycles). The 
3 RACE primer sequence was designed from a consensus of se- 
q, ences which have wide homology among the CAPI8 family. PCR 
p, oducts were cloned into a TA cloning vector (Invitrogen). After 
isolation of clones, sequencing analysis was performed using the 
IV 13 reverse and forward primers. 
2. 7. Tissue-specific expression of HCAP18 in PBMC by Western Blot 
and RT-PCR analysis 
Granulocytes were separated from monocytes/platelets using Ficoll 
75 
gradient centrifugation with Histopaque-l119 and Histopaque-1077. 
After resuspension f the cells in an appropriate volume of PBS, one 
part of the cells was used for the purification of mRNA using the 
Novagen (Madison, WI) mRNA purification kit and the other part of 
the cells was extracted for Western blot analysis by boiling after 
resuspension of the cells with 2 X SDS sample buffer. The samples 
were loaded onto 4-20% SDS PAGE, and transferred to nitrocellulose 
membrane after electrophoresis. Titered polyclonal rabbit antibody 
(diluted 1:500) prepared against HCAP18 prosequences (amino acids 
1 105) was applied to the blot. After washing, blots were exposed to 
preabsorbed polyclonal goat anti-rabbit heavy chain antibody (diluted 
1:200) followed by use of the enhanced chemiluminescence W stern 
blot analysis ystem (Amersham). The mRNAs from monocytes and 
granulocytes were reverse-transcribed with random hexamer primers 
using StrataScript reverse transcriptase (Stratagene) for the synthesis 
of cDNA. The primers HUCAP no. 1 and HUCAP no. 2 primers 
(sequences above) were used to amplify DNA under the following 
PCR conditions: 95°C, 5 min; then 35 cycles of 94°C, 1 min; 55°C, 
1 min; 72°C, 1 min; followed by 72°C, 7 min. The PCR products were 
electrophoresed in a 2% agarose gel and visualized by ethidium bro- 
mide staining. The gel was transferred to a nitrocellulose membrane 
and hybridized with an internal HCAP18 specific primer (HC4: 5'- 
CCCACGATGGATGGGGACCCAGAC-3'). For a control, the hu- 
man [3-actin control amplimer set was used. 
3. Results 
3.1. Genomic structure o f  HCAP18 gene 
A human genomic DNA library constructed in lambda 
EMBL3 was screened by hybridization with an HCAP18 spe- 
cific probe prepared by PCR. Seven positive plaques were 
detected out of 3x  106 plaques screened. All of the clones 
had the same restriction map (data not shown). A representa- 
tive clone (no. 12) was subjected to further analysis. An 8 
kilobase size EcoRI fragment was subcloned into pUC18 
and sequenced bidirectionally. Fig. 1A presents a schematic 
representation of the HCAP18 gene, cDNA and protein. Fig. 
1B presents the entire sequence of the HCAP18 gene. The 
HCAP18 coding sequence is assembled from 4 exons covering 
2 kb of DNA.  The transcription initiation site is located 16 
nucleotides upstream from the first ATG. The 5' upstream 
DNA does not contain typical TATA box or CCAAT se- 
quences. Inspection of the sequence revealed that exon 4 con- 
tains the entire C-terminal antimicrobial domain. However, in 
addition to encoding the known antimicrobial peptide this 
exon also encodes an additional six residues located on the 
N-terminal end of the antimicrobial peptide. 
3.2. Assignment o f  the HCAP18 gene to human chromosome 3,
band p21.3 
PCR amplification with HCAP18-specific primers generated 
a 177 bp fragment from human DNA as expected and no 
product from Chinese hamster DNA. Amplif ication of the 
human x Chinese hamster mapping panel gave positive results 
only in those hybrid cell lines that had retained human chro- 
mosome 3. All other human chromosomes were excluded by 
the presence of discordant hybrids (Table 1). Furthermore, 
specific PCR amplification was obtained from a hybrid cell 
line (XII-2D-2a aza) containing two copies of the short arm of 
chromosome 3, but not from another hybrid cell line (XVII I-  
7B-3a aza) retaining only the long arm of chromosome 3. 
These results indicated that the HCAP18 gene is located on 
the short arm of chromosome 3. 
Fluorescence in situ hybridization independently confirmed 
the result from the somatic cell hybrid mapping panel. Of  24 
metaphase spreads analyzed, 20 exhibited a specific fluores- 
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-698 ttttttcatactgagtctcactctgttacccaggctggagtgcagtggcatgatctcagc 
-638 taactgcaacttctgcttcccgggttcaatgggttcaag£gattctcatgcctcagcttg 
-578 tagctgggaactactggtgtgagccatcatgcgtggctaattttcatatttttagtagag 
-518 atggggtttcaccatgttggccaagcttgtctcgaactccttatctcaggtgatccgccc 
-458 accttggcctcccaaagtgctgggattataggcgtgcagaccgtgccctgcctcattcat 
-398 caattcttaatcgatgcctacagggtgccaggcaatgctagagctggagatttagcagtc 
-338 catcatactgactcctgaggagtagaaggatgtagaataggcacctggctctcttcctct 
-278 ctggagggatttaacgctcttgagcacccctggctatgacaatctccggtcaggtctggg 
-218 aggttgtcagagatgaagaaaccacttcctcatcttgcacacaaggaaggcctcactcac 
-158 tgcccagcaagtcctg/gaagcaatagccagggctaaagcaaaccccagcccacaccctg 
-98 gcaggcagccagggatgggtggatcaggaaggctcctggttgggcttttgcatcaggctc 
-38 aggctgggcataaaggaggctcctgtgggctagagggaGGCAGACATGGGGACCATGAAG 
23 ACCCAAAGGGATGGCCACTCCCTGGGGCGGTGGTCACTGGTGCTCCTGCTGCTGGGCCTG 
83 GTGATCGCTCTGGCCATCATTGCCCAGGTCCTCAGCTACAAGGAAGCTGTGCTTCGTGCT 
143 ATAGATGGCATCAACCAGCGGTCCTCGGATGCTAACCTCTACCGCCTCCTGGACCTGGAC 
203 CCCAGGCCCACGATGgtgagctttgggggacattctgctctgctctggctgggcttggca 
263 cgtgttgttccttctgctcctgctgcactgcctgccaggagggcatctccccctttaaat 
323 gtggtcccgtgttttccagggaaccttctagagctcgtgtctcctcccagctcgagagct 
383 tctgccttataattcctgctgtggcagagatccctcaccccgaccccacgcaggttttg'g 
443 gacttctgcgagctccaggcactagaatggggtcattggctctgggcagtgacctcctct 
503 gctttaagtctcttctgtaccacgttaccccacatagggaagaactctatccagacttta 
563 ggttccagtgggcatgtcttgtcccccaggaagccccctgacttcccttgcccccacccc 
623 agagtgggaggggctccttgttagagctcatctgaggtctgctcctactcactgttcacc 
683 taggagggtaggaatggctcagtcctcctcccctcaatgccccagtgccaagcccagcac 
743 ccagtgcccgtcgcacatcaggtactgtggaaagcctgccctcttggtggggaggtcatg 
803 gacacaaatcagaaaatacaagaatgggcctccccatttcctcctctgactagGATGGGG 
863 ACCCAGACACGCCAAAGCCTGTGAGCTTCACAGTGAAGGAGACAGTGTGCCCCAGGACGA 
923 CACAGCAGTCACCAGAGGATTGTGACTTCAAGAAGGACGGGgtgaggctgggggctgggg 
983 gtgttggtgggtgcctcccaaggagctgaacagggggcacctggggaatatttcccactg 
1043 ggatgtggctgggaggtcatggcaaatggtttcaagtttgaccttgagcttctcctttcc 
1103 agCTGGTGAAGCGGTGTATGGGGACAGTGACCCTCAACCAGGCCAGGGGCTCCTTTGACA 
1163 TCAGTTGTGATAAGgtgagtgggctgttctgggatgcaggggctgatgggggcatagagt 
1223 gtggaccatccaatgggtcaattaactactcccccaacccaggacagagaaagcccctcc 
1283 tacccagggctcttccccaaacctgagttccatctccagggccggctctggaatccctta 
1343 gagcggtagatctccaagtgtagcccttcctggggactcgttagatatgcaaattctcag 
1403 gccctactcagacctactcagacagactctgggtagggcccagaaattcgtattttgata 
1463 agctttccaggagattccggcttctgtaaagtttgagagccactgtctaagagtactcag 
1523 ctctcagccctgtgttcccatctcagtgttgctgggctgggctgtgtgaccctgcagagc 
1583 ccctcactatctccgggactctgttttctcatctttttattgggtgtagggattcaatca 
1643 catgcttcaaaggtcacagccagaggttgaactggggccccaaagctctgcgggggccca 
1703 cgaagaggggcgtctaggtggggaggggtcttggattgaccctgggtacatccccgacaa 
1763 ggaacctgtttcttcctgtacacaaccccagGATAACAAGAGATTTGCCCTGCTGGGTGA 
1823 TTTCTTCCGGAAATCTAAAGAGAAGATTGGCAAAGAGTTTAAAAGAATTGTCCAGAGAAT 
1883 CTAGGATTTTTTGCGGAATCTTGTACCCAGGACAGAGTCCTAGTGTGTGCCCTACCCTG 
1943 GCTCAGGCTTCTGGGCTCTGAGAAATAAACTATGAGAGCAATTTCctcaggcttcagtct 
2003 cacttgttttgcctcctctctctcaccacaactgagcccttagctcagggagtccacgtg 
2063 tgagtgtgagtgtgtgtgagtgtgacacagaggtggcgagggcagtgttccatccaggag 
2123 gacacagggtaa 
Fig. 1. (A) Schematic structure of the human CAPI8 gene. (B) Sequence of the human CAP18 gene. The HCAP18 gene is comprised of 4 exons 
(capital letters) spread over approx. 3 kb including 700 bases of 5' upstream sequence from the transcription initiation site. The borders of the 
three introns do not interrupt codons. Exon 4 contains the entire C-terminal antimicrobial domain with an additional six amino acids at its 
N-terminus. Initiation and termination codons are shown in bold. 
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Fi~. 2. (Left) Chromosomal localization of the human HCAP18 gene by fluorescence in situ hybridization (FISH) of a gene-specific lambda 
clone. Specific signals (indicated by arrowheads) are present on human chromosome 3 at bands p21.3. (Right) Ideogram of human chromosome 
3 [~5] illustrates the somatic ell hybrid (SCH) and the FISH localization of HCAP18 gene. The vertical bars represent the portion of chromo- 
soTae 3 retained in two somatic hybrid cell lines and the plus and minus signs symbolize the positive and negative PCR amplifications using 
H~ 'AP 18-specific primers. 
ce'at signal on both chromatids of a single chromosome 3, and 
13 of these had signals on both chromosome 3 homologs. The 
ch "omosomes were identified based on an R banding pattern 
produced by BrdU incorporat ion in late S-phase after syn- 
ch ~onization of the cells. The localization of the signal corre- 
spmds  to band 3p21.3 (Fig. 2). No other chromosomal site 
w~s labeled above background. 
3... Characterization of  5' upstream region 
Fo identify sequences important  o promoter activity, 5'- 
Ta ole 1 
truncations were introduced into the pGL3 reporter vector 
containing a luciferase reporter gene. The promoterless luci- 
ferase plasmid (pGL3-Basic) and the luciferase plasmid under 
the control of the cytomegalovirus enhancer promoter (pGL3- 
Control) were used as negative and positive transfection con- 
trol, respectively. After each construct was transfected into 
Cos 7 or K562 cells for 2 days, the cells were harvested and 
lysates assayed for luciferase activity using a scintillation 
counter. Each luciferase construct was co-transfected with a 
pCMV-13-galactosidase v ctor, an internal standard for the 
C~ mparison of HCAPI8 PCR product with human chromosomes in human × Chinese hamster somatic ell hybrids 
P( R product/ Human chromosome number 
C1 romosome 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X 
D~ ~cordant hybrids 
4 ' -  6 6 0 5 8 3 8 5 7 8 5 4 4 2 5 3 10 6 4 6 3 5 3 
/+ 3 0 0 2 2 3 1 3 1 0 2 2 2 3 3 2 2 4 5 3 3 4 2 
C~ ncordant hybrids 
~'+ 3 4 9 4 2 6 1 5 2 2 5 6 6 8 5 5 0 4 5 4 7 5 1 
/ -  2 4 4 2 3 2 3 2 3 5 1 3 2 2 2 3 3 1 0 2 1 0 1 
Informative hybrids 
% discordance 
14 14 13 13 15 14 13 15 13 15 13 15 14 15 15 13 15 15 14 15 14 14 7 
64 42 0 53 67 43 69 53 61 53 54 40 43 33 53 38 80 67 64 60 43 64 71 
Dzt ta for chromosomes with rearrangements or present at low copy number ( < 0.1) were excluded. For each chromosome the number of hybrid cell 
lines are listed in 4 categories defined by the presence (+) or absence ( - )  of the HCAP18-specific PCR product and the presence (+) or absence ( - )  
of the respective chromosome. The % discordance is calculated as the sum of discordant over total informative hybrids for each chromosome. 
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Activity of HCAP18 5' upstream region 
HCAP18 5' UTR I 
700 bp 
t 
500 bp 
I 
4OO bp 
:3(X) bp 
200 bp 
[ 
1®..~ 
CMV 
[ 
Basic I. 
Luclfemse reporter gene 
promoter Activity (cpm) 
COS 7 1(562 
j 182129 48 
I 120165 52 
J 395973 42 
! s~,~l  33 
] 282153 64 
] 145 35 
I 1426014* 2437653* 
I 45 56 
33 47 Mock 
shown). Further studies will be required to confirm the ab- 
sence of multiple human CAP18 peptides. 
3.5. Granulocyte specific expression of HCAP18 in PBMC by 
Western blot, RT-PCR analysis and Northern blot 
Northern blots revealed the HCAP18 mRNA to be approx. 
800 bp in length similar to that previously reported for the 
rabbit [1]. Northern analysis of a large number of tissues 
showed that only bone marrow contains HCAP18 transcripts 
(Fig. 4A). Among the various subsets of cells present in per- 
ipheral blood, only granulocytes expressed the HCAP18 gene 
(see Fig. 4B). In addition using RT-PCR and Western blot 
methods, HCAP18 was not detected in various leukocyte cell 
lines including K562, HL60 and U937. 
"CMV samples were diluted to 1/250 for [udferase assay. 
Fig. 3. Promoter activity of HCAP18 5' upstream region. 5'-trunca- 
tions of the HCAP18 promoter constructed using PCR were intro- 
duced into the luciferase reporter plasmid. The promoterless lucifer- 
ase plasmid and the luciferase plasmid under the control of the 
cytomegalovirus enhancer promoter were used as negative and posi- 
tive transfection controls, respectively. Cos 7 cells (5x 105) were 
transfected with 2 lag of each construct. The amount of luciferase 
was determined after 48 h by scintillation counter, and the results 
were normalized for protein content and [3-galactosidase activity 
(measured from a [3-galactosidase cotransfection). Values represent 
the mean of three representative experiments. CMV samples were 
diluted to 250-fold. 
transfection efficiency, using Lipofectamine as described 
above. 
The luciferase activities of these constructs in Cos 7 cells are 
shown in Fig. 3. HCAP18 promoters containing reater than 
300 nucleotides of upstream sequence reproducibly express 
greater than 3000-fold more luciferase activity than the pro- 
moterless vector with maximum activity demonstrated by the 
300 bp construct (649 000 cpm). However, in Cos 7 cells the 
CMV promoter is approx. 2000 times stronger than the stron- 
gest HCAP18 promoter construct. Among the HCAP18 pro- 
moter constructs, the 300 and 400 bp constructs have the 
highest activity. No HCAPI8 reporter activity was detected 
in K562 cells. These results were confirmed by visual observa- 
tion of [~-galactosidase staining (revealed by the X-gal sub- 
strate) of Cos 7 cells transfected with the 300 bp HCAP18- 
promoter driving [3-galactosidase (data not shown). 
3.4. Attempt o find novel HCAP18 family members by 
3' RACE 
Previously, several laboratories demonstrated a family of 
porcine proteins called protegrins hown to be homologous 
to CAP18 [15-17] and related bovine proteins [18]. Although 
these proteins have 60-70% amino acid identity between hu- 
man and porcine species in the conserved cysteine-rich pro- 
sequence, there is considerable divergence in the amino acid 
sequences of the C-terminal domains (see table in [1]). There- 
fore, an effort was made to identify other HCAP18 family 
members. For this purpose mRNA from human bone marrow 
and peripheral blood leukocytes was subjected to 3' RACE. 
No novel mRNAs were identified from among 12 bone mar- 
row clones and 5 leukocyte clones. The polyadenylation site 
was not precisely conserved among these clones: several 
clones had TTC(A), whereas others had TT(A),, (data not 
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0 0 0 G~ 
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Fig. 4. (A) Northern blot analysis demonstrates HCAP18 expression 
in bone marrow tissue. Northern blots from 15 different tissues 
were purchased from Clontech. Blots were probed with an 
HCAPl8-specific probe (HC4, 107 cpm) prepared form the HCAP18 
eDNA using a random labelling kit from Promega. The major band 
is at 800 bp (markers not shown). (B) Specific expression of 
HCAPI8 mRNA in granulocytes: RT-PCR analysis. Approx. 
2 X 107 cells were isolated from a human buffy coat. RNA was puri- 
fied, and RT-PCR carried out as described in methods. An end-la- 
belled internal primer was used to detect amplified DNA. Holo- 
HCAP18 is specifically amplified only in purified granulocytes. The 
amplified band is 450 bp (markers not shown). (C) Specific expres- 
sion of HCAP18 protein in granulocytes: Western blot analysis. 
Samples prepared from approx. 2x107 cells (see Section 2) were 
electrophoresed on a 4-20% SDS-PAGE gel and electroblotted onto 
a nitrocellulose membrane. The membrane was immunoblotted with 
a titered antibody against the HCAP18 prodomain according to 
methods. Holo HCAP18 is found only in purified granulocytes. The 
positive band is located at a molecular mass of approx. 16.5 kDa 
(markers not shown). 
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4. Discussion 
(!AP18 is one of the recently identified PMN antimicrobial 
preteins [1]. Holo-CAP18 is comprised of two functional do- 
mams. The C-terminal domain of 37 amino acids forms 
[1920] an amphipathic a-helix to bind LPS and mediates 
ant i-bacterial activity against both Gram-positive and Gram- 
negative organisms [21,22]. In vivo studies indicate that the 
an~i-microbial domain of CAP18 has protective activity in a 
pig model of endotoxemia [23]. 
although the amino acid sequence and pattern (four con- 
sel md cysteines within a sequence of approx. 100 amino 
aci~ts) of the N-terminal domain are more conserved than 
the quite diverse C-terminal fragments, the function of this 
cysteine rich pro-sequence is not known. Perhaps it serves to 
pr,.tect and localize CAP18 to its subcellular location in the 
sptcific granules of mature neutrophils [24]. 
!tuman CAP18 maps to chromosome 3 band p21.3 in the 
vic nity of a number of other genes, including macrophage- 
stimulating factor-1 or hepatocyte growth factor like-protein 
(lVlST1, HGF), guanine nucleotide binding protein alpha in- 
hil itory subunit 2 (GANI2), myosin light chain 3 (MYL3), 
gaiactosidase beta-1 (GLBI), collagen VII alpha-1 polypep- 
tici: (COL7A1), cholecystokinin (CCK), and natural killer 
trii,~gering receptor (NKTR). The mouse counterparts of these 
genes have been mapped to a conserved syntenic region on 
distal mouse chromosome 9 (data from [25,26],). Therefore, 
w( predict hat the mouse homolog of HCAPI 8 is also located 
or. mouse chromosome 9. At the present ime, neither human 
re.,.ion 3p21.3 nor the homologous mouse chromosome 9 re- 
gi~ n is known to carry genes for any inherited disorders or 
ph motypic trait suggestive of HCAP18 involvement. 
geveral families of functionally related proteins with lipo- 
pc, ysaccharide binding and antimicrobial ctivity are found to 
be clustered in the human genome. Both LPS binding protein 
(k ~P) and bactericidal permeability increasing protein (BPI/ 
C,,P57) are located on chromosome 20ql 1.12-q23 [27], while 
az trocidin (CAP37) resides on chromosome 19pl 3.3, together 
wi h at least two other family members, neutrophil elastase 
an t proteinase 3 [28]. HCAP18 shares a significant homolo- 
go is sequence at its N-terminal domain with a similar protein 
fr~ m pig [29] and sheep [30] myeloid cells, the indolicidin 
pr,~tein from cows [31], and an antibacterial 15 kDa protein 
(p 5s, pl5H) from human leukocytes [32], suggesting a novel 
m~tltigene family. It is likely that HCAPI8 is also located in a 
ch ster with other members of this family of related genes. 
Fhe cloning of genomic DNA for HCAP18 forms the 
gr mndwork for analysis of the genetic regulation of this anti- 
m~¢robial protein during differentiation. The HCAP18 gene is 
ce nprised of 4 exons spanning 3 kb including 700 bp of 5' 
upstream DNA. Like the previously characterized protegrin 
ge le, the HCAP18 gene has a short 5' untranslated region (16 
nt and a promoter lacking typical TATA box or CCAAT 
sequences. Several granulocyte-specific proteases (azurocidin, 
pr )tease 3, neutrophil elastrase, cathepsin G, and myeloper- 
ox dase) are expressed at the promyelocytic or promonocytic 
st~ ge of myeloid differentiation. The promoters of these five 
ge les share TATA-Iike elements, a CCAAT box, a PU. 1 bind- 
in: site and a CT-rich element within the first 200 bp of the 
m,dor transcriptional start site. In contrast, the promoters of 
m"eloid genes expressed at later stages of granulocyte/macro- 
phage maturation, such as CD22B, CD18, and CD11C, lack 
the 'TATA' box as well as the Ets/PU. 1 binding site. Because 
the HCAP18 promoter structure is more like this later group 
of proteins, HCAP18 gene expression may only occur during 
later stages of granulocyte maturation. In fact, the RT-PCR 
experiments on mature granulocytes upport the idea that 
HCAP18 is expressed uring a late stage of differentiation 
(Fig. 4B). Failure to find expression of HCAP18 (by RT- 
PCR or Western blot) in HL60 (promyelocytic cell line) and 
U937 (monocytic lineage), both undifferentiated hematopoie- 
tic cell lines, also supports this idea. It is probable that the 
positive HCAPI 8 Northern blot of bone marrow is the result 
of contaminating mature PMNs. In other work CAP18 
mRNA was found in testis [32]. Thus, like lactoferrin [33], 
HCAP18 may be a useful marker to characterize disorders 
of granulocyte terminal differentiation, such as acute leukemia 
and the myelodysplastic syndrome. 
Technical problems thwarted the facile characterization f 
the HCAP18 promoter. Efforts to transfect various promoter 
constructs into HL60 and U937 cells were not successful. 
Crystal's laboratory [34] also noted difficulty in transfecting 
HL60 cells. Our attempts to transfect HL60 cells with plasmid 
vectors were also unsuccessful despite trying a variety of avail- 
able methods. Sequences of the HCAP18 promoter spanning 
300400 bp upstream can be demonstrated to have modest 
promoter activity in Cos 7 cells, albeit at a rather low level 
compared to a standard CMV driven reporter gene. Since 
physiologically relevant CAP18 expression is not expected in 
such cells, it is possible that the observed activity represents 
the basal activity of the 'core' promoter. However, none of the 
5' upstream fragments howed even this basal activity in the 
erythromyeloid line, K562, suggesting that HCAP18 gene ex- 
pression occurs only in the later stages of neutrophil matura- 
tion and is under tight control. Future studies will be required 
to delineate the precise nature of this fascinating stage and 
tissue-specific regulation. 
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